Dr. Bryan A. Faller, MD
Hematology & Oncology (Hematology & Oncology Physician)
3015 N Ballas Rd
Saint Louis, MO 63131
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 277
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MO license 2006002688
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Parkland Health Center Farmington, MO
- Parkland Health Center - Bonne Terre Bonne Terre, MO
Medical groups
- Missouri Baptist Physician Services LLC (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 277
- Services billed
- 1,017
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 471 | 168 |
| Established patient office or other outpatient visit, 40-54 minutes | 139 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 56 | 42 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 50 | 20 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 34 companies reported 70 payments worth $1,518 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $150 |
|---|---|
| Genentech USA, Inc. | $139 |
| AbbVie Inc. | $107 |
| Novartis Pharmaceuticals Corporation | $106 |
| Janssen Biotech, Inc. | $72.45 |
| GlaxoSmithKline, LLC. | $71.72 |
| Gilead Sciences, Inc. | $62.88 |
| Stemline Therapeutics Inc. | $55.51 |
| Food and Beverage | $1,518 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $765,381 in research payments for these studies, mostly to the institutions running them.
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441 - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc. - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - Chemo trastuzumab vs chemo trastuzumab pertuzumab
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.